argenx on X: "Today we announced the continuation of our chronic inflammatory demyelinating polyneuropathy (CIDP) program following interim analysis of the Phase 2/3 ADHERE trial. Learn more here: https://t.co/0vgXZk0o0u https://t.co/iv5KRcJfH8" / X
ARGENX SE Form 6-K Current Report Filed 2023-01-09
Myasthenia Gravis Foundation of America, Inc. - argenx announces positive topline results from Phase 3 ADAPT trial for gMG. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia
argenx | News
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis | Business Wire
Genmab expands immunology reach in argenx pact
Argenx Files for FDA Approval of Efgartigimod for Generalized MG
argenx | News
argenx | News
Karen Gluck - Quality Control Editor - argenx | LinkedIn
ARGENX SE - VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
Generalized Myasthenia Gravis Market and Epidemiology 2032:
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Business Wire
Press Releases | Argenx
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Latest Healthcare and Pharma Press Release | Latest Healthcare News
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis | Business Wire
Argenx's Potential Blockbuster Gets FDA Nod for Autoimmune Disease
argenx | News
ELITE 2023 Marketing Team VYVGART Brand Launch Team of argenx | PM360